Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis

ConclusionA significant proportion of patients with severe colitis failing IV steroids responded to induction therapy with CT-P13. Colectomy-free survival rates were similar to previous randomized trials using originator infliximab as induction therapy in severe steroid-refractory colitis.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research

Related Links:

When Joe Silverman developed Crohn’s disease at age 21, the symptoms started out mild. While the sight of blood in his stools initially freaked him out, what really bothered him was the frequent abdominal pain and bloating that occurred as his condition progressed to moderate and then severe. Dietary changes didn’t make a difference, so he began taking prescription oral anti-inflammatory drugs that are often used to treat certain bowel diseases, which alleviated but didn’t eliminate his discomfort. He started using prescription steroid suppositories to cope with flare-ups of the inflammatory bowel disease...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: news
Genes, Vol. 12, Pages 1477: Expression of Cytokine-Coding Genes BMP8B, LEFTY1 and INSL5 Could Distinguish between Ulcerative Colitis and Crohn’s Disease Genes doi: 10.3390/genes12101477 Authors: Daša Jevšinek Skok Nina Hauptman Miha Jerala Nina Zidar Ulcerative colitis (UC) and Crohn’s disease (CD) are characterized by an imbalance between pro-inflammatory and anti-inflammatory cytokines, interfering with the resolution of inflammation. Due to the crucial role of cytokines, new insights into their profiles in UC and CD would help to improve our understanding of pathogenesis and enabl...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
The risk of inflammatory bowel disease (IBD) within families continues to be elucidated, and data are lacking on this topic in Asian countries. In this issue of Clinical Gastroenterology and Hepatology, Kim and colleagues1 conducted a retrospective cohort study within the South Korea National Health Insurance Database, from 2002-2017. This data source is derived from the universal health system in South Korea, is population-based, and specifically includes family history information. From a cohort of nearly 22 million individuals, the investigators identified 45,717 with ulcerative colitis and 17,848 with Crohn ’s di...
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Issue Highlights Source Type: research
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
Conclusions: The originator and SB-2 biosimilar-infliximab behaved similarly in several currently used assays in their concentrations in biological fluids. Clinicians can be confident that therapeutic drug monitoring using platforms designed and developed for the originator-infliximab can be applied to SB-2-infliximab.
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Short Communication Source Type: research
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
Gastroenterol Res Pract. 2021 Aug 31;2021:5536563. doi: 10.1155/2021/5536563. eCollection 2021.ABSTRACTInflammatory bowel disease includes ulcerative colitis (UC) and Crohn's disease (CD) of unknown etiology. The expression of ATP-binding cassette (ABC) family proteins has been associated with drug resistance and development of UC. The cystic fibrosis transmembrane conductance regulator (CFTR) or also known as ABCC7 is involved in the inflammatory chronic response. The aim of this study was to evaluate the role of ABCC7/CFTR in UC patients and normal controls without inflammation. This is an exploratory, observational, and...
Source: Gastroenterology Research and Practice - Category: Gastroenterology Authors: Source Type: research
Linda Ann Sasser has had ulcerative colitis since she was 20, but it wasn’t until May 2019, about 30 years later, that her condition hit a low point: not only did she have a major flare-up of chronic inflammatory bowel disease (IBD), but on top of it, she had Clostridioides difficile (or C. diff), a highly contagious bacterial infection that causes severe diarrhea and inflammation of the colon. “I became really, really sick with bloody diarrhea 30 times a day and chronic stomach pain,” Sasser says. While hospitalized for 12 days, she was given oral steroid medications, which didn’t help, then IV ste...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Disease feature Source Type: news
ConclusionThe NSG-CD model partially reflects the human disease and allows for studying the development of fibrosis.
Source: Immunity, Inflammation and Disease - Category: Allergy & Immunology Authors: Tags: ORIGINAL ARTICLE Source Type: research
CONCLUSION: Although cross-reactivity is expected between one biological agent to another, in our case the use of Adalimumab as alternative choice post Tumor necrosis factor Inhibitor (TNF) -α (Remsima infliximab) induced hemolysis did not cause hemolysis or any type of reaction.PMID:34484733 | PMC:PMC8403549 | DOI:10.1016/j.amsu.2021.102768
Source: Annals of Medicine - Category: Internal Medicine Authors: Source Type: research
More News: Colectomy | Crohn's Disease | Endoscopy | Gastroenterology | Inflammatory Bowel Disease | Laboratory Medicine | Remicade | Study | Ulcerative Colitis